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In this study, we report the case of a patient infected with
human immunodeﬁciency virus (HIV)-1 who developed ataxia
and neurocognitive impairment due to viral escape within the
central nervous system (CNS) with a multidrug-resistant
HIV-1 despite long-term viral suppression in plasma. Anti-
retroviral therapy optimization with drugs with high CNS
penetration led to viral suppression in the CSF, regression of
ataxia, and improvement of neurocognitive symptoms.
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CASE PRESENTATION
We describe the case of a 50-year-old patient who was diag-
nosed with human immunodeﬁciency virus (HIV)-1 in 1995.
The patient started antiretroviral therapy (ART) in 1998
with a CD4 cell count of 71 cells/µL and an HIV viremia of
46 000 copies/mL. Sustained viral suppression was achieved
after starting an ART with zidovudine (AZT), lamivudine
(3TC), and efavirenz (EFV) (Figure 1). The patient elected to
interrupt ART in 2002, at which point his HIV viremia was un-
detectable. After 2 years, the patient’s CD4 dropped to 43 cells/
µL and HIV viremia was raised to 73 700 copies/mL. At that
time (October 2004), the drug resistance for HIV-1 in plasma
showed no resistance mutations. Antiretroviral therapy with
tenofovir (TDF), emtricitabine (FTC), and ritonavir-boosted
atazanavir (ATV/r) was reintroduced. This regimen suppressed
HIV-1 in plasma for the next 9 years, and CD4 cells stabilized at
approximately 600 cells/µL.
Because the course of treatment was favorable, the patient
only came for the routine examinations in our clinic every 6
months. At his visit in April 2013 he was asymptomatic. At
the end of November in 2013, during his next scheduled exam-
ination, the patient complained about severe gait ataxia, head-
aches, persisting fatigue, as well as memory difﬁculties for 2
months, which forced him to stop his work as a bus driver.
We initiated a comprehensive work up including detailed neu-
rological investigations, blood and cerebrospinal ﬂuid (CSF)
analysis, neuroimaging, and neuropsychological testing.
In January 2014, the CSF showed a mononuclear pleocytosis
with 75 cells/µL, an elevated protein of 985 mg/L, a normal glu-
cose of 3.4 mmol/L, and 1184 HIV-1 RNA copies/mL, whereas
HIV-1 in plasma was below 20 copies/mL. Human immunode-
ﬁciency virus-1 viral load in plasma and in CSF was quantiﬁed
using Cobas TaqMan HIV-1 version 2.0 (Cobas Ampliprep;
Roche Diagnostic, Basel, Switzerland) with a detection limit
of 20 copies/mL. Drug resistance testing in HIV-1 reverse-
transcriptase and protease using bulk sequencing of the
CSF-HIV-1 RNA showed 2 nucleoside reverse-transcriptase
inhibitor (NRTI) resistance-associated mutations (M184 V
and K65R) and 1 non-NRTI (NNRTI) resistance-associated
mutation (K103N). The cerebral magnetic resonance image
showed increased signal on T2-weighted images in the subcort-
ical and periventricular white matter, as well as in the basal gan-
glia and thalamus, without contrast enhancement (Figure 2).
The only pathological ﬁnding in the neurological examina-
tion was the patient’s tendency to fall to the left side during a
straight-line walking test. The neuropsychological evaluation
conﬁrmed neurocognitive impairments in executive functions,
attention, working and nonverbal memory, speed of informa-
tion processing, visuospatial abilities, and motor skills. Because
functional impairments in everyday life were reported, the pa-
tient was diagnosed with HIV-associated mild neurocognitive
disorder (Supplementary Appendix 1). Laboratory investiga-
tions revealed no alternative etiologies for the neurological
symptoms. Explicitly, the duplex sonography of the brain-
supplying arteries was normal with no signs of cerebrovascular
disease. Moreover, there were no metabolic or neoplastic diseas-
es that could have explained the neurological deﬁcits.
Four months after ART intensiﬁcation with AZT, 3TC, rito-
navir-boosted darunavir (DRV/r), and raltegravir (RAL), the
cellularity in CSF normalized to 1 cell/µL and HIV viral load
was successfully suppressed. The protein level (0.84 mg/L) was
still slightly elevated, and the glucose (3.89 mmol/L) was in a
normal range. During the following months, the subjective
complaints of equilibrium disturbance, headache, fatigue, and im-
paired memory progressively resolved. A follow-up neurological
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examination conﬁrmed the total regression of the ataxia with
a normal neurological status, including a normal straight-line
walking test.
Nevertheless, the neuropsychological follow up 18 months
after baseline testing showed only minimal regression of the
neurocognitive deﬁciencies, with attention, speed of informa-
tion processing, visuospatial abilities, and motor skills beeing
similar to baseline; however we obeserved signiﬁcant improve-
ment in verbal memory, nonverbal divergent thinking, and ori-
entation memory. The questionnaire of Instrumental Activities
of Daily Living showed no more impairments in daily life func-
tioning. Because objectively neurocognitive impairments were
still present, but without impairements in daily functioning,
the patient was diagnosed with HIV-associated asymptomatic
neurocognitive impairment.
DISCUSSION
We describe the case of a 50-year-old patient infected with
HIV-1 presenting with subacute neurological symptoms due
to a “viral escape encephalitis” in the CSF with a multidrug-
resistant virus. Human immunodeﬁciency virus, in addition
to its tropism for the immune system, has a tropism for the cen-
tral nervous system (CNS) [1, 2]. In general, HIV infection of
the CNS responds well to combined ART. However, in some
patients, HIV RNA is detectable in the CSF despite plasma
viral control, or the CSF HIV-RNA level is ≥1 log greater
than the plasma HIV-RNA level. This rare condition has
been deﬁned as “CSF escape”. There are conﬂicting studies
regarding the exact clinical relevance of CSF escape: Eden
et al [3] found asymptomatic CSF escape in 7 of 69 (10%)
patients on ART, with a median of 121 copies/mL (interquartile
range, 54–213 copies/mL) in the CSF. Cerebrospinal ﬂuid viremia
above 1000 cp/mL, such as that found in our case, were not found
in these patients. Canestri et al [4]and Peluso et al [5]each report-
ed a case series of 11 and 10 patients with CSF escape and neu-
rological symptoms, respectively. The median CSF viral load of
these patients was 880 copies/mL (range, 558–12 885 copies/mL)
Figure 1. Human immunodeficiency virus (HIV) viremia, CD4 cell count, and antiretroviral therapy from 1998 to 2014. Abbreviations: ATV, atazanvir; AZT, zidovudine; CPE,
central penetration effectiveness; DRV, darunavir; EFV, efavirenz; FTC, emtricitabine; II, integrase inhibitors; NLV, nelfinavir; NNRTIs, nonnucleoside reverse-transcriptase in-
hibitors; NRTIs, nucleoside reverse-transcriptase inhibitors; PI, protease inhibitors; RAL, raltegravir; RTV, ritonavir; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine.
Figure 2. Magnetic resonance imaging showing confluent T2-hyperintense signal
changes.
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and 3900 copies/mL (range, 134–9056 copies/mL), respectively,
which is higher than in the case series of asymptomatic patients
described by Eden et al [3] but comparable to the viral load in
the CSF of our patient.
It is remarkable that at the time of neurological complaints,
the patient’s antiretroviral regimen had been unchanged for 9
years, which is much longer than in the above-mentioned
case series, where the time of unchanged ART was 13 and 21
months, respectively. The HIV-1 RNA in the CSF of our patient
harbored 2 NRTI (M184V and K65R) and 1 NNRTI (K103N)
resistance-associated mutations. It is notable that the K103N
mutation was preserved for 14 years after stopping NNRTI ther-
apy. We assumed that the drug resistance mutations M184V
and K103N emerged during or after discontinuation of treat-
ment with AZT, 3TC, and EFV because these mutations were
not present at diagnosis of HIV infection. It is possible that
stopping these drugs simultaneously led to exposure to EFV
monotherapy given the long half-life of this compound facilitat-
ing the emergence of NNRTI resistance [6]. We cannot prove
that these resistance mutations originally developed in the
CNS because no resistance test in plasma was performed in
2002 immediately after discontinuing the ﬁrst ART regimen.
However, the fact that we could not detect the M184V nor
the K103N resistance mutations in the plasma before we restart-
ed ART in October 2004 could be a hint that the mutations orig-
inally developed in the CNS. The second ART regimen with TDF,
3TC, and ATV/r achieved a sustained viral suppression in plasma;
however, an autonomous replication and independent evolution
of the HIV-1 harboring the K65R mutation (typically associated
with virological failure of TDF) in the CSF occurred. This isolated
mutation could have emerged in the CSF because the cerebral
virus already harbored the M184V mutation, and thus the
second treatment regimen was less effective in the CNS compared
with plasma. The occurrence of isolated resistance-associated
mutations in the CSF has been reported previously. In the
above-mentioned case series, Canestri et al [4] found resistance-
associated mutations in 7 of 8 CSF HIV-RNA strains, and Peluso
et al [5] found resistance-associated mutations in 6 of 7 CSF
HIV-RNA strains. They found resistance mutations for NRTI,
NNRTI, and protease inhibitors (PI) [4]. This result emphasizes
the importance of performing a resistance test in patients with
viral escape in the CSF.
Letendre et al [7] have proposed the CNS penetration-
effectiveness (CPE) score to estimate the drug penetration
into the CNS and the correlation with CSF-HIV replication.
Remarkably the CPE score of the second ART regimen with
TDF, 3TC, and ATV/r in our patient had a low CPE score of
only 5. Considering that presumably the HIV-1 already har-
bored the M184V mutation when this regimen was started,
the adjusted CPE score was only 3. This low CPE score may
have contributed to the development of the K65R mutation in
CSF and the consequent viral escape in CSF. When we tailored
the salvage ART of our patient, we ﬁrst considered the resis-
tance pattern of the HIV-1 found in the CSF, but we also choose
substances with an increased CPE score. We changed the PI ata-
zanavir/ritonavir (CPE = 2) to darunavir/ritonavir (CPE = 3)
and added AZT (CPE = 4) and RAL (CPE = 3) to achieve a
high total CPE score of 12 or 10, considering the resistance-
associated mutations in the CSF. With this treatment regimen,
viral suppression in the CSF could be achieved within 4 months.
In addition, the CSF pleocytosis normalized to 1 cell/µL.
Our case is further proof that compartmentalization of HIV-
1 replication in the CNS can occur in patients taking ART reg-
imen with poor intracerebral penetration. In addition to the low
CSF drug concentration and treatment interruption, the im-
paired cellular immunity of our patient with a low CD4 nadir
of only 43 cells/µL may have contributed to his viral escape in
CSF. Several studies have described an association between low
CD4 counts and neurocognitive impairment [8]. All of these
factors probably contributed to symptomatic multidrug-
resistant HIV replication in the CSF despite suppressed plasma
viremia, which is a rare event. Similar to the patients of the
above-mentioned case series, the viral escape encephalitis
symptoms of our patient improved after optimizing ART. Atax-
ia as well as subjective complaints such as headaches and fatigue
resolved, resulting in no more impairments in daily life func-
tioning. However, follow-up neuropsychological examination
showed only minimal regression of neuropsychological impair-
ment, which we attribute to potential irreversible intracerebral
damage occurring during a long-lasting, undiscovered, ongoing
cerebral HIV-1 replication.
CONCLUSIONS
Patients infected with HIV-1 with neurological complaints war-
rant further investigation of the CSF including measurement of
HIV viral load and genotypic resistance testing, because isolated
replication of HIV with drug-resistant variants can rarely occur
despite viral suppression in plasma. Optimizing ART by using
drugs with improved CNS penetration may achieve viral sup-
pression in CSF with improvement of neurological symptoms.
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